D
espite the recent advances in medical therapies, patients with Crohn's disease (CD) continue to require surgical interventions at a high rate, with an estimated lifelong likelihood of surgery of up to 80%. 1 This frequently entails the creation of either a temporary or a permanent stoma. Approximately 10% of CD patients will need a permanent stoma at a certain stage of their disease course. 1 The potential need for an ostomy is among the top concerns for patients with inflammatory bowel disease (IBD). [2] [3] [4] [5] [6] [7] This concern has been noted to be independent of disease subtype and severity and persisted when patients were assessed longitudinally over a 1-year period. 7 Nevertheless, data about the actual impact of ostomy on functional status and health-related quality of life (HRQOL) of IBD patients are very limited. Furthermore, IBD patients with ostomies are frequently excluded from clinical research because many of the tools used to assess disease activity and HRQOL do not apply to this subpopulation (e.g., questions on bowel movement frequency).
Few studies have linked having a stoma to a number of adverse psychosocial outcomes including depression and anxiety, increased loneliness, lowered self-esteem, poorer body image, and sexual disturbances. [8] [9] [10] [11] However, the majority of these studies were qualitative in nature and were not restricted to IBD patients. In fact, 2 of the above-referenced studies were in non-IBD patients who required an ostomy for an underlying malignancy. 9, 11 IBD patients who frequently suffer from severe and refractory disease before proceeding with a surgery may perceive living with an ostomy differently. For example, in a study by Nordin et al 12 evaluating HRQOL and psychosocial distresses in 492 IBD patients, of which 67 (14%) reported an ileostomy, patients with ileostomy had better social functioning, emotional functioning, and fewer bowel symptoms compared with those with ileoanal anastomosis. Furthermore, when compared with patients without ileostomy but with comparable disease extent, patients with ileostomies had similar levels of HRQOL and comparable anxiety and depression scores to those with no ileostomy.
In this study, we aimed to assess the subset of CD patients within the Crohn's and Colitis Foundation of America (CCFA) Partners cohort study who had an ostomy for a minimum duration of 6 months as compared with those patients with CD and no ostomy and to investigate the impact of ostomy on specific patient-reported outcomes (PROs) including anxiety, depression, fatigue, pain interference, sleep disturbances, social satisfaction, and sexual interest and satisfaction.
MATERIALS AND METHODS

Study Design
We performed a cross-sectional analysis of a subset of CD patients within the CCFA Partners cohort who had an ostomy for a minimum duration of 6 months.
Study Population
CCFA Partners is a longitudinal Internet-based cohort of adult IBD patients, which has been ongoing since 2011. The development of the cohort has been previously described. 13 In brief, after a baseline survey, participants are invited to complete follow-up surveys every 6 months. At baseline and at each follow-up interval, data on demographics, disease subtype and characteristics, medications, measures of disease activity, and various PROs are collected. All data are self-reported. Within this cohort, we identified our study population as all CD patients completing 2 surveys 6 or more months apart who reported either having or not having an ostomy at both time points (N ¼ 4733).
Study Variables
Disease activity was assessed using the Manitoba IBD Index (MIBDI). MIBDI is a validated, single-item, patientdefined, disease activity measure.
14 Patients are asked to select the statement that best describes their disease activity over the past 6 months from these categories: (1) constantly active, giving me symptoms every day; (2) often active, giving me symptoms most days; (3) sometimes active, giving me symptoms on some days (for instance 1-2 d/wk); (4) occasionally active, giving me symptoms 1 to 2 d/mo; (5) rarely active, giving me symptoms on a few days in the past 6 months; and (6) I was well in the past 6 months, what I consider a remission or absence of symptoms. Patients with any of (1) (2) (3) (4) answers are considered to have active disease, whereas those choosing answers 5 or 6 are considered to be in clinical remission. The short IBD Questionnaire (SIBDQ) (Short Inflammatory Bowel Disease Questionnaire [SIBDQ] was authored by Dr. J. Irvine, et al, was made under license from McMaster University, Hamilton, Canada) was used to assess HRQOL. For each participant, levels of anxiety, depression, fatigue, sleep disturbances, pain interference, social satisfaction, and sexual interest and satisfaction were assessed using the PatientReported Outcomes Measurement Information System (PROMIS). The PROMIS measures have been previously validated in general and in chronically ill populations, and their performance has also been assessed within the CCFA Partners cohort. [15] [16] [17] In brief, participants completed 2 to 4 items for each of the PROMIS domains. The items are then calibrated using t-score metric to provide a mean value for the domain assessed, where higher scores indicates higher level of the domain being measured (e.g., more anxiety or more social satisfaction). In the generally healthy populations, the mean t-score for anxiety, depression, fatigue, pain interference, sleep disturbances, and social satisfactions is 50 with standard deviation (SD) of 10. A priori thresholds of $52 (anxiety, depression, fatigue, pain interference, and sleep disturbances) and #48 (social satisfaction) were selected to define the presence of an adverse PRO within each domain. We chose these threshold cut points to allow for a clinically meaningful separation from the general population. Minimal important differences in PROMIS measures for IBD patients have not been defined. However, in cancer patients, chronic pain patients and healthy pediatric patients, research has revealed a range of minimal important differences of 2 to 6 for several of the PROMIS domains. [18] [19] [20] The mean t-scores within the general population for the domains of sexual interest and satisfaction are gender specific: 50 (10) in men and 42 (14) in women for sexual interest and 51 (9) in men and 49 (11) in women for sexual satisfaction. 21 
Statistical Analysis
Descriptive statistics were used to describe the demographic and disease-related characteristics of the studied population stratified by the presence or absence of ostomy. Continuous variables were presented as mean and SD, whereas the categorical variables were reported as percentages. We performed statistical tests of group differences using Pearson's chi-square test for categorical variables and Student's t-tests for continuous variables. Within strata defined by disease activity, multivariable logistic regression models were then used to investigate independent associations between ostomy status and anxiety, depression, fatigue, pain interference, sleep disturbances, and social satisfaction while controlling for participants' age, body mass index, disease duration, gender, smoking status, and IBD therapies. The main outcomes of interest in these logistic models were the presence of adverse PROs defined as mean $ 52 for anxiety, depression, fatigue, pain interference, and sleep disturbances and #48 for social satisfaction. One-way between-groups analysis of covariance was used to assess the impact of having an ostomy on sexual interest and satisfaction while controlling for the participant's age and disease activity. We also used logistic regression modeling to assess predictors of narcotic use. All statistical analyses were performed using SPSS version 22.0 (IBM, Corp, Armonk, NY).
Ethical Considerations
The Institutional Review Board at the University of North Carolina approved the study protocol.
RESULTS
Patient Characteristics
A total of 4733 CD patients were included in the study. Of these, 402 patients (8.5%) reported an ostomy on both their baseline and first follow-up surveys (minimum duration of 6 months). Patients with ostomy were older (mean age, 49.3 years) and had longer disease duration (mean, 26.2 months) compared with those with no ostomy (mean age, 43.7 years and mean disease duration, 15.1 months). Both groups were comparable in regard to race and gender distributions, body mass index, and the proportion of current smokers ( Table 1) . As measured by the MIBDI, more patients with ostomy were in clinical remission compared with those without ostomy (48.5% for ostomy versus 31.3% for no ostomy; P , 0.001).
The frequencies of IBD medications use by patients with and without ostomies are shown in Table 1 . Overall, patients with ostomies were less likely to use IBD medications than those without ostomies (50% versus 65%; P , 0.001). The majority of ostomy patients treated with medications reported the use of a biologic agent (40.5%) or an immunomodulator (56.9%). A total of 13.6% patients with ostomy reported being on 5-aminosalicylate therapy. The rate of systemic corticosteroid use was similar for patients with and without ostomy (12.8% versus 15.3%; P ¼ 0.21).
Interestingly, narcotic use was higher among patients with an ostomy as compared with those without ostomy (21.5% versus 14.7%; P ¼ 0.001). Using logistic regression modeling to assess independent predictors for narcotic use among the study population while controlling for disease activity and several demographic and disease-related characteristics, having an ostomy was an independent predictor for narcotic use (odds ratio [OR], 1.68; 95% confidence interval [CI], 1.24-2.27). Other predictors included in the model are listed in Table 2 .
Impact of Ostomy on Quality of Life and PROs
Because disease activity is likely to influence the HRQOL and the various PROs, the impact of ostomy on these outcomes was examined within strata defined by disease activity. On bivariate analysis, the HRQOL as assessed by the SIBDQ was comparable for patients with and without ostomy within each strata of disease activity (Table 3) . Among those in clinical remission, the scores for all 6 PROMIS domains (anxiety, depression, fatigue, pain interference, sleep disturbances, and social satisfaction) were comparable in patients with and without ostomy. However, for patients whose disease activity is not controlled, those with ostomy had worse PROMIS scores for fatigue, pain interference, and social satisfaction compared with those with no ostomy (Table 3) . Using logistic regression models to investigate independent (adjusted) associations between ostomy and the 6 PROs within strata defined by disease activity, having an ostomy was noted to be an independent predictor for fatigue (OR, 1.66; 95% CI, 1.15-2.39), pain interference (OR, 1.63; 95% CI, 1.12-2.35), and reduced social satisfaction (OR, 1.42; 95% CI, 1.03-1.95) among patients with active disease. Conversely, among those who were in clinical remission, ostomy was only associated with reduced social satisfaction (OR, 1.68; 95% CI, 1.19-2.38) but none of the other assessed outcomes (Fig. 1) .
For patients who completed the sexual function domains (n ¼ 1326 for sexual interest domain and n ¼ 991 for sexual satisfaction domain), mean scores for sexual interest and satisfaction were similar in both patients with and without ostomy, which remained true after adjusting for age and disease activity (Table 4) .
DISCUSSION
The potential need for an ostomy is a major concern for patients with IBD, particularly CD patients who may be at higher risk of needing a permanent ostomy. Nevertheless, up until now, the data on the actual impact of having an ostomy in this population were very limited. In this large sample of CD patients, we analyzed the demographic and disease-related characteristics of patients with ostomy for a minimum duration of 6 months compared with those without ostomy. Furthermore, we investigated the impact of having an ostomy on several PROs pertaining to different functional and psychosocial domains. We observed several important findings. First, as expected, patients with ostomy were older and had longer disease duration compared with those without an ostomy. This is likely a reflection of the general notion that surgery is reserved as a last resort for patients with CD after failing several medical therapies.
Second, patients with an ostomy were more likely to be in clinical remission compared with those without an ostomy (48.5% versus 31.3%, respectively). This is mirrored by the observation that only half of the patients with ostomy reported being on any IBD therapy. For CD patients, in whom the disease can involve any part of the gastrointestinal tract, surgery is not considered or advocated as a cure. However, those with primarily colonic disease have higher chances of maintaining long-term clinical remission after colectomy with a suggested advantage of ileostomy over anastomosis. 22, 23 In a study by Bernell et al, 22 the cumulative 10-year risk of a symptomatic recurrence after colectomy with ileorectal anastomosis was 58% compared with 24% after colectomy with ileostomy. The outcome is likely different for patients requiring ostomy for other indications, particularly those with refractory perianal disease. Our sample likely includes patients who received their ostomy for multiple indications.
Despite the higher prevalence of clinical remission, patients with ostomy were more likely to report narcotic use compared with those without ostomy (21.5% versus 14.7%, respectively). The higher rate of narcotic use in patients with ostomy persisted even among patients reporting remission based on the MIBDI (9.7% in patients with ostomy versus 5.5% in patients without ostomy). Furthermore, in the logistic regression modeling, having an ostomy was an independent predictor for narcotic use after controlling for age, gender, disease activity, smoking status, and pain interference. Within the CCFA Partners cohort, patients are not asked to specify which narcotic agents they are using. Hence, it is possible that the higher rate of narcotic use among patients with ostomy in our study is related to using this class of therapy to reduce ostomy output (e.g., tincture of opium) rather than managing pain. However, ostomy patients with active disease had a much higher prevalence of narcotic use compared with those with ostomy but in remission (32.5% versus 9.7%, respectively) and also compared with nonostomy patients with active disease (19%), suggesting that narcotic may be used to control disease symptoms in a significant proportion of patients with ostomy. This is further supported by the noted association between narcotic use and pain interference scores (Table 2) . Narcotic use in IBD patients has been linked to a number of adverse effects, including higher rate of infectious complications, surgical complications, and even mortality. [24] [25] [26] Thus, further research is needed to understand the nature of pain in CD patients with ostomy and provide appropriate alternatives to narcotic-based analgesia in this population. In our study, having an ostomy did not impact HRQOL as measured by SIBDQ. Although SIBDQ is an IBD-specific quality of life (QOL) measure, it is important to note that this questionnaire has not been separately validated in patients with ostomy. Hence, our results should be interpreted in the context of this limitation. Nevertheless, our findings are comparable to results from 2 previous studies that used a generic QOL tool, the Short Form 36 (SF-36) questionnaire, to assess the impact of ostomy on HRQOL among IBD patients. 12, 27 In both studies, ostomy did not have a significant impact on HRQOL.
In regards to the 6 assessed PROMIS domains, having an ostomy seems to primarily impact social satisfaction given our observed association between ostomy and reduced social satisfaction irrespective of active/remission disease status. This impact of ostomy on social satisfaction may be related to an altered body image and the technical issues related to daily ostomy care. In a study by Carlsson et al, 27 the Rating Form of IBD Patients Concerns questionnaire was used to assess the concerns of patients with ileostomy. Producing unpleasant odor and being a burden on others were among the top 5 concerns, both of which can impact social functioning and satisfaction. We also observed significant associations between ostomy status and both fatigue and pain interference among patients with clinically active disease but not for those in clinical remission. It is unclear whether these associations represent a causal effect of ostomy in this population or, alternatively, ostomy serves as a surrogate marker for more severe and complicated disease with resultant pain and fatigue in patients who continue to have active disease despite prior surgical intervention. At a more reassuring note, having an ostomy did not impact anxiety, depression, or sleep disturbances scores even in patients with active disease, and ostomy was not associated with pain interference or fatigue among those in remission.
Finally, in our study population, having an ostomy did not impact sexual interest or satisfaction in both men and women, even after adjusting for age and disease activity. This is contrary to what has previously been reported in the literature as having an ostomy was linked to a number of adverse physiological and psychological effects that can impact sexual function in both men and women. Among those effects are erectile dysfunction; retrograde ejaculation; orgasmic dysfunction; dyspareunia; and reduced sexual desire. 28, 29 The discrepancy between our results and the prior literature is likely related to the indication for the ostomy, IBD, rather than malignancy. This is particularly true for the physiological effects resulting from nerve damage caused by more extensive surgical resection and manipulation needed for cancer resections but not typically for IBD-related surgeries. It is also important to note that a smaller proportion of patients completed the sexual function modules in our study, which may have an impact on the power of our results.
There are several strengths to this study. It is, to our knowledge, the largest to date to assess the characteristics of CD patients with ostomy and investigate its impact on several PROs. Furthermore, the studied population was part of a well-maintained and geographically diverse cohort of IBD patients. In a validation study from a subset of participants in the parent cohort, there was a 97% accuracy rate of self-reported IBD status and disease subtypes when compared with medical records. 30 The use of validated scales to assess a wide variety of clinically relevant PROs is also a strength of this study. Finally, using the MIBDI, we were able to conduct analyses stratified by disease activity in both patients with and without ostomy.
We also recognize a number of limitations to our study. We were unable to determine the indication for having an ostomy in each patient, the exact time since surgery, and whether the ostomy is permanent or temporary. In addition, the disease location and behavior could not be specified for each patient. These characteristics may influence how patients perceive the impact of having an ostomy on their QOL. To mitigate this limitation and minimize the variability, we only analyzed patients who reported the same ostomy status in 2 subsequent surveys, and we used the responses in the second survey to assess the impact on the various PROs. A second limitation is the use of SIBDQ to assess HRQOL. As we pointed out earlier, the SIBDQ is not validated in ostomy patients. Furthermore, one item in the questionnaire is not applicable to patients with ostomy (pertaining to tenesmus). Several stomaspecific QOL questionnaires were proposed in the past. [31] [32] [33] Those questionnaires are relatively long (20-34 items), and none of them is specific for IBD patients; hence, we elected to use the SIBDQ. The relatively smaller proportion of patients completing the sexual function modules is another limitation because we were unable to use regression modeling to control for multiple variables in a manner similar to our analyses of the other PROs. Nevertheless, we were able to control for age and disease activity in our calculations, both are expected to have greater impact on sexual function.
In conclusion, in this cross-sectional study of CD patients, having an ostomy did not impact the QOL or sexual function of the patients. Moreover, ostomy was not associated with anxiety, depression, or sleep disturbances. The majority of ostomy-adverse PROs associations, with the exclusion of social satisfaction, were only observed in patients with active disease. Therefore, it is reassuring that the presence of an ostomy concomitant with controlled disease does not impact important PROs. These data will aid in counseling individuals facing a surgical need for temporary or permanent stoma creation.
